Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
Status:
Terminated
Trial end date:
2020-07-06
Target enrollment:
Participant gender:
Summary
Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or
ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.